Goods & Services

Providing educational services, namely a program to provide long-term on-farm training and courses in the field of swine health; organizing and conducting of workshops, seminars and training courses for veterinary care and animal-health management, including online and via the Internet in the field of swine health. Providing online information on diagnosis, prophylaxis and therapies of pig diseases, via a global communication network.

Abstract

The present invention provides a high-throughput method for determining dsRNA editing activity of an A-to-l RNA editing enzyme in a competition assay and particularly this high- throughput method allows for screening of inhibitors of an A-to-l RNA editing enzyme, as well as a medium-throughput method for screening and validating of inhibitors of an A-to-l RNA editing enzyme at single A-to-l editing site. Additionally, a high-throughput method is provided for determining binding of a dsRNA binding protein, particularly an A-to-l RNA editing enzyme, to a dsRNA target, and particularly this high-throughput method can be used for screening or characterizing inhibitors of dsRNA binding proteins.

IPC Classes  ?

• G01N 33/542 - ImmunoassayBiospecific binding assayMaterials therefor with immune complex formed in liquid phase with steric inhibition or signal modification, e.g. fluorescent quenching
• C12N 15/11 - DNA or RNA fragmentsModified forms thereof

Abstract

The present invention refers to the combination of the HER2 tyrosine kinase inhibitor zongertinib with an anti-HER2 antibody and/or an anti-HER2 antibody-drug conjugate. Such combination may further comprise an additional anti-cancer medicament. The combination of the invention is useful for the treatment and/or prevention of oncological and/or hyperproliferative diseases, such as cancer. Accordingly, compounds for use, methods of prevention and/or treatment, uses, pharmaceutical compositions and kits related to the combination are herewith provided.

IPC Classes  ?

• A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
• A61K 31/337 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
• A61K 31/357 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
• A61K 31/505 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim
• A61K 31/513 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
• A61P 35/00 - Antineoplastic agents
• C07K 16/32 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products from oncogenes

Abstract

The invention relates to a modified mammalian glutamine synthetase comprising a mutation at amino acid position 10 and/or 298 in a mammalian glutamine synthetase, wherein the mutation is selected from the group consisting of R298K, N10S, N10T and N10Q and to an expression vector, a nucleic acid and a eukaryotic host cell encoding said modified mammalian glutamine synthetase and to its use as a selection marker. The invention further relates to methods for preparing stable cell lines, or for producing a protein of interest using said modified mammalian glutamine synthetase for selection.

IPC Classes  ?

• C12N 9/00 - Enzymes, e.g. ligases (6.)ProenzymesCompositions thereofProcesses for preparing, activating, inhibiting, separating, or purifying enzymes
• C07K 16/00 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies
• C12N 15/85 - Vectors or expression systems specially adapted for eukaryotic hosts for animal cells

Goods & Services

Promoting public awareness of clinical trials Downloadable and recorded software for providing information on clinical trials Educational services, namely, providing web based interactive multimedia software featuring audio and video information for patients on clinical trials

Abstract

The invention relates to solid pharmaceutical dosage forms comprising an extended release core comprising metformin hydrochloride and one or two immediate release coatings comprising linagliptin and/or empagliflozin.

IPC Classes  ?

• A61K 9/24 - Layered or laminated unitary dosage forms
• A61K 9/16 - AgglomeratesGranulatesMicrobeadlets
• A61K 9/20 - Pills, lozenges or tablets
• A61K 31/155 - Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (HN=C(OH)NH2), isothiourea (HN=C(SH)—NH2)
• A61K 31/522 - Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
• A61K 31/7048 - Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin
• A61P 3/10 - Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Abstract

The present invention relates to a method for detecting carboxylesterase activity of contaminating host cell protein in a sample comprising a recombinant protein of interest produced in a eukaryotic cell in cell culture comprising contacting the sample with the hydrophilic substrate HPTS ester and optionally in addition separately contacting the sample with a lipophilic substrate 4-MU ester and detecting the carboxylesterase and optionally lipase activity of the at least one contaminating host cell protein using the hydrophilic and optionally lipophilic substrate by detecting the fluorescence intensity of the released chromophore. Further provided is a method for manufacturing a recombinant protein of interest comprising using the method for detecting carboxylase activity of a contaminating host cell protein in a sample comprising a recombinant protein of interest produced in a eukaryotic cell in cell culture using a hydrophilic substrate and optionally further a lipophilic substrate for determining contaminating carboxylesterase and/or lipase activity in the sample comprising the recombinant protein of interest during manufacture.

IPC Classes  ?

• C12Q 1/44 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving hydrolase involving esterase
• G01N 33/58 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving labelled substances

Abstract

The present invention refers to the combination of the HER2 tyrosine kinase zongertinib with a KRAS G12C inhibitor. The combination of the invention is useful for the treatment and/or prevention of oncological and/or hyperproliferative diseases, such as cancer. Accordingly, compounds for use, methods of prevention and/or treatment, uses, pharmaceutical compositions and kits related to the combination are herewith provided.

IPC Classes  ?

• A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
• A61P 35/00 - Antineoplastic agents

Abstract

The invention refers to an improved method of manufacturing Intermediate (VIII), wherein in step a) 5-Chloro-2-iodo-pyrimidine and boc-boronic ester (V) are reacted in the presence of the catalyst bis(amphos)palladium-II-chloride to yield Intermediate (VI) and wherein in step b) Intermediate (VI) is hydrogenated to yield the non-isolated Intermediate (VII) and wherein in step c) the non-isolated Intermediate (VII) is reacted with hydrochloric acid to yield Intermediate (VIII). The invention further related to a method of manufacturing Intermediate (XVIII), which is substantially enantiomerically pure with a content of ≤ 0.5 % of the unwanted enantiomer ent-XVII, preferably with an enantiomeric excess over the unwanted enantiomer ent-XVII of at least 99.88 %, and with a content of less than 30 ppm of titanium, whereby this substantially enantiomerically pure Intermediate (XVII) was manufactured by steps a), b), c) and d) as described in claim 18. The invention additionally refers to a method of recrystallizing Intermediate (XIX) from a mixture of 5 VP of n-propanol and of 1.25 VP of water to yield the PDE4B-inhibitor of formula (XX) in the crystalline form B.

IPC Classes  ?

• C07D 495/04 - Ortho-condensed systems
• C07D 401/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring- member bond

Abstract

The present invention refers to the combination of the HER2 tyrosine kinase inhibitor zongertinib with an anti-HER2 antibody and/or an anti-HER2 antibody-drug conjugate. Such combination may further comprise an additional anti-cancer medicament. The combination of the invention is useful for the treatment and/or prevention of oncological and/or hyperproliferative diseases, such as cancer. Accordingly, compounds for use, methods of prevention and/or treatment, uses, pharmaceutical compositions and kits related to the combination are herewith provided.

IPC Classes  ?

• A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61P 35/00 - Antineoplastic agents
• A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment

Abstract

The present invention refers to the combination of the HER2 tyrosine kinase zongertinib with a KRAS G12C inhibitor. The combination of the invention is useful for the treatment and/or prevention of oncological and/or hyperproliferative diseases, such as cancer. Accordingly, compounds for use, methods of prevention and/or treatment, uses, pharmaceutical compositions and kits related to the combination are herewith provided.

IPC Classes  ?

• A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
• A61P 35/00 - Antineoplastic agents

Abstract

The present invention relates to the field of oncolytic viruses and in particular to a recombinant rhabdovirus, such as vesicular stomatitis virus encoding in its genome for a gasdermin. The invention is further directed to the use of the recombinant virus in the treatment of cancer and also to methods for producing such viruses.

IPC Classes  ?

• C12N 7/00 - Viruses, e.g. bacteriophagesCompositions thereofPreparation or purification thereof
• A61K 35/76 - VirusesSubviral particlesBacteriophages
• C12N 15/86 - Viral vectors
• A61K 35/766 - Rhabdovirus, e.g. vesicular stomatitis virus

Abstract

The present invention relates to a measuring arrangement with a flow cell. The flow cell is arranged in such a way that the fluidic sample flows from bottom to top through the flow cell. The fluidic sample flows through the flow cell within a residence time which is greater than 1 second. Additionally or alternatively, the measuring arrangement comprises a pumping device to pump the fluid forwards and backwards through the flow cell during measurement. It is possible to reduce and/or prevent air bubbles in the flow cell. In this way it is possible to reduce and/or prevent the negative influence of gas bubbles on the measurement.

IPC Classes  ?

• G01N 21/05 - Flow-through cuvettes
• G01N 21/11 - Filling or emptying of cuvettes
• G01N 21/85 - Investigating moving fluids or granular solids
• G01N 35/10 - Devices for transferring samples to, in, or from, the analysis apparatus, e.g. suction devices, injection devices
• G01N 21/65 - Raman scattering

Goods & Services

dietary supplements for treating fatigue; nutritional supplements for boosting energy; nutritional supplements for promoting healthy skin

Goods & Services

Medicinal preparations for the treatment of pain; Medicinal preparations for the treatment of fever

Abstract

A method is described for the prophylaxis of hypertension in a cat in need thereof. The method includes administration of an effective amount of angiotensin II receptor 1 (AT-1) antagonist (sartan) to the cat, wherein the prophylaxis of hypertension is a delay of onset of hypertension.

IPC Classes  ?

• A61K 31/4184 - 1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
• A61P 9/12 - Antihypertensives

Abstract

A method is described for the prophylaxis of hypertension in a cat in need thereof. The method includes administration of an effective amount of angiotensin II receptor 1 (AT-1) antagonist (sartan) to the cat, wherein the prophylaxis of hypertension is a delay of onset of hypertension.

IPC Classes  ?

• A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
• A61K 31/4178 - 1,3-Diazoles not condensed and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
• A61K 31/4184 - 1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61P 9/12 - Antihypertensives

Abstract

The present invention generally relates to pharmaceutical formulations which are useful for treating acute coronary syndrome. More specifically, the invention pertains to a novel pharmaceutical formulation which comprises a myeloid-derived growth factor (MYDGF) protein which is useful for treating a myocardial infarction in a subject in need thereof. The pharmaceutical formulation of the invention provides a significantly improved long-term stability compared to commonly used formulations. In addition, the pharmaceutical formulation of the invention allows an easy lyophilisation and reconstitution without any significant loss of the therapeutically active protein. The invention also pertains to a formulation for use in a method for treating a myocardial infarction in a subject in need thereof. The method comprises an intravenous administration of a MYDGF protein to the subject on top of standard of care.

IPC Classes  ?

• A61K 38/18 - Growth factorsGrowth regulators
• A61K 9/08 - Solutions
• A61K 47/18 - AminesAmidesUreasQuaternary ammonium compoundsAmino acidsOligopeptides having up to five amino acids
• A61K 47/22 - Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
• A61K 47/26 - Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharidesDerivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin

Abstract

The present invention generally relates to pharmaceutical formulations which are useful for treating acute coronary syndrome. More specifically, the invention pertains to a novel pharmaceutical formulation which comprises a myeloid-derived growth factor (MYDGF) protein which is useful for treating a myocardial infarction in a subject in need thereof. The pharmaceutical formulation of the invention provides a significantly improved long-term stability compared to commonly used formulations. In addition, the pharmaceutical formulation of the invention allows an easy lyophilisation and reconstitution without any significant loss of the therapeutically active protein. The invention also pertains to a formulation for use in a method for treating a myocardial infarction in a subject in need thereof. The method comprises an intravenous administration of a MYDGF protein to the subject on top of standard of care.

IPC Classes  ?

• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 9/08 - Solutions
• A61K 9/19 - Particulate form, e.g. powders lyophilised
• A61K 47/18 - AminesAmidesUreasQuaternary ammonium compoundsAmino acidsOligopeptides having up to five amino acids
• A61K 47/26 - Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharidesDerivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
• A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Goods & Services

Scientific research in the field of medicine; providing medical and scientific research information in the field of pharmaceuticals, namely, providing information relating to specific pharmaceutical trials and clinical trials; all of the foregoing excluding the provision of an on-line searchable database and excluding information for use at the point of patient care and in pharmacies

Goods & Services

Scientific research in the field of prevention and treatment of metabolic and cardiovascular diseases; providing medical and scientific research information in the field of metabolic and cardiovascular diseases.

Goods & Services

Downloadable computer software applications for assisting patients with the management of symptoms of central nervous system diseases and disorders and mental illness and disorders; Downloadable computer software for assisting patients with the management of symptoms of central nervous system diseases and disorders and mental illness and disorders; Downloadable computer application software for mobile phones, namely, software for assisting patients with the management of symptoms of central nervous system diseases and disorders and mental illness and disorders Medical and scientific research in the field of mental health; providing medical research and scientific research information in the field of mental illness and disorders Health care services, namely, therapeutic services for patients with symptoms of diseases and disorders of the central nervous system; Health care services, namely, therapeutic services for patients to support mental health

Abstract

The present invention relates to the processing of an auscultation signal that preferably has a periodicity, wherein the auscultation signal is generated by an auscultation device comprising an acoustic pickup for auscultating sounds and a signal converter that is physically and acoustically coupled to the acoustic pickup, for converting the auscultated sounds into the auscultation signal, wherein the auscultation signal is divided into signal intervals, whereby auscultation signal portions are formed, and wherein the auscultation signal portions are overlaid and a result signal is formed by processing and by examining the density of the overlaid auscultation signal portions.

IPC Classes  ?

• A61B 7/00 - Instruments for auscultation
• A61B 7/04 - Electric stethoscopes

Goods & Services

Medical and scientific research in the field of prevention and treatment of metabolic disease in horses; Providing medical and scientific research information

Abstract

The present invention encompasses compounds of the formula (I), wherein R1, R2.a, R2.b, R3.a, R3.b, R4.a, R4.b, R5, R6, R7, R8, R9, R10, R11, R12, R13, R14, R15, R16, R17, R18, Rx, n and Q have the meanings given in the claims and specification, their use as inhibitors of mutant Ras family proteins, pharmaceutical compositions and preparations containing such compounds and their use as medicaments/medical uses, especially as agents for treatment and/or prevention of oncological diseases. The present invention encompasses compounds of the formula (I), wherein R1, R2.a, R2.b, R3.a, R3.b, R4.a, R4.b, R5, R6, R7, R8, R9, R10, R11, R12, R13, R14, R15, R16, R17, R18, Rx, n and Q have the meanings given in the claims and specification, their use as inhibitors of mutant Ras family proteins, pharmaceutical compositions and preparations containing such compounds and their use as medicaments/medical uses, especially as agents for treatment and/or prevention of oncological diseases.

IPC Classes  ?

• C07D 413/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
• A61K 31/506 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Abstract

The present invention relates to a novel N-[(Pyrimidinylamino) propanyl]-arylcarboxamide derivative, its pharmaceutical compositions containing it and its use in therapy, particularly in the treatment or prevention of conditions having an association with the GPR88-receptor.

IPC Classes  ?

• C07D 403/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
• A61K 31/506 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings

Abstract

The invention refers to an isolated nucleic acid sequence encoding a peptide tag comprising amino acid sequence SEQ ID NO:1 for expression of a protein or peptide of interest (POI) in a host cell, wherein said nucleic acid sequence comprises SEQ ID NO:2 comprising at least 3 silent mutations at positions selected from the group consisting of: a. codon encoding Pro at position 1 of SEQ ID NO:1, wherein CCG has been modified to CCC or CCA; b. codon encoding Arg at position 3 of SEQ ID NO:1, wherein CGC has been modified to AGG, AGA or CGA; c. codon encoding Asn at position 4 of SEQ ID NO:1, wherein AAC has been modified to AAT; d. codon encoding Glu at position 6 of SEQ ID NO:1, wherein GAG has been modified to GAA; e. codon encoding Arg at position 7 of SEQ ID NO:1, wherein CGA has been modified to AGG, or AGA; and f. codon encoding Lys at position 8 of SEQ ID NO: 1, wherein AAG has been modified to AAA.

IPC Classes  ?

• C12N 15/67 - General methods for enhancing the expression
• C12P 21/02 - Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
• C12N 15/62 - DNA sequences coding for fusion proteins
• C12N 15/70 - Vectors or expression systems specially adapted for E. coli

Abstract

The present invention relates to bispecific antibodies binding to CD277 and to a human tumor-antigen. The present invention relates also to polynucleotides encoding such bispecific antibodies and to vectors and host cells comprising such polynucleotides. In addition, the present invention relates to methods for producing such antibodies and to methods of using such antibodies in the treatment of diseases and their therapeutic use.

IPC Classes  ?

• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
• C07K 16/40 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against enzymes

Abstract

The present invention relates to a method of optically inspecting bottles comprising producing one or more digital representations by optically sensing one of the bottles, and automatically analyzing the one or more digital representations for identifying anomalies, wherein the optically sensing comprises optically sensing an external appearance of the one of the bottles, preferably while the uptake volume is empty, such that at least one of the analyzed digital representations characterizes the external appearance, and wherein the optically sensing comprises optically sensing an internal appearance at least of a bottom of the one of the bottles through the opening while the uptake volume is empty such that at least one of the analyzed digital representations characterizes the internal appearance of the bottom. Further, the present invention relates to a system and a computer program as well as a computer-readable medium for performing the method.

IPC Classes  ?

• G01N 21/90 - Investigating the presence of flaws, defects or contamination in a container or its contents

Goods & Services

administration of a program for enabling participants to obtain discounts on animal health products and services; providing advertising, marketing and promotional services, namely, development of promotional advertising campaigns for web pages for a discount program for animal health products providing a website featuring information in the field of animal health products and veterinary services

Goods & Services

Downloadable computer software and downloadable mobile applications for assisting patients with symptoms of central nervous system diseases and disorders; downloadable computer software and downloadable mobile applications to assist patients with mental illness and disorders. Therapeutic services for patients with symptoms of diseases and disorders of the central nervous system; therapeutic services for patients to support mental health.

Goods & Services

Medical and scientific research in the fields of respiratory diseases, inflammatory diseases and autoimmune diseases; providing medical and scientific research information in the field of respiratory diseases, inflammatory diseases and autoimmune diseases.

Abstract

The present disclosure is directed to a method for determining the shear stress sensitivity of eukaryotic or prokaryotic cells in a shear stress sensitivity device (100) during a cultivation process, comprising: (1) providing a shear stress sensitivity device (100), (2) selecting cells, liquid culture medium, cultivation mode and conditions; (3) selecting one, two or three stress parameters; (4) characterizing the shear stress sensitivity device (100) for the maximum shear stress by a calibration method; (5) performing the same cultivation process several times and measuring one or more performance characteristics of the cells during each run and generating a curve for each performance characteristic in each run over time; (6) performing the cultivation process as a control having a lower maximum shear stress than in step (5); and (7) selecting the curve from the set of curves of step (5) that is closest to the control curve while obtaining the shear stress sensitivity or limit for the cells.

IPC Classes  ?

• C12M 1/00 - Apparatus for enzymology or microbiology
• C12M 1/42 - Apparatus for the treatment of microorganisms or enzymes with electrical or wave energy, e.g. magnetism, sonic wave

Abstract

[00121] The present invention relates to a label-free, high throughput method for determining an infectious virus titer in an aqueous sample comprising infectious virus, wherein the method comprises detecting the kinetics of morphological cell alteration, such as cell rounding, following viral infection, determining a parameter defining the curve of the morphological cell alteration as a function of time post infection and determining the infectious virus titer based on a standard curve of the infectious virus at a known infectious titer.

IPC Classes  ?

• C12N 7/00 - Viruses, e.g. bacteriophagesCompositions thereofPreparation or purification thereof
• C12Q 1/70 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving virus or bacteriophage

Abstract

This invention relates to binding molecules that bind specifically to CD137 and FAP and their use in medicine, pharmaceutical compositions containing the same, and methods of using the same as agents for treatment and/or prevention of cancer.

IPC Classes  ?

• C07K 16/40 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against enzymes
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61P 35/00 - Antineoplastic agents
• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants

Abstract

The present invention relates to a method for identification of common patient-spanning tumor-specific T cell receptors (TCRs) and their corresponding antigens. The invention also relates to these TCR sequences, a nucleic acid encoding the TCR, and a T cell comprising the TCR and/or the encoding nucleic acid.

IPC Classes  ?

• G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing
• A61K 35/17 - LymphocytesB-cellsT-cellsNatural killer cellsInterferon-activated or cytokine-activated lymphocytes
• A61K 40/11 - T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cellsLymphokine-activated killer [LAK] cells
• A61K 40/32 - T-cell receptors [TCR]
• C07K 14/725 - T-cell receptors
• C12N 15/10 - Processes for the isolation, preparation or purification of DNA or RNA
• C12Q 1/6806 - Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay
• C12Q 1/6809 - Methods for determination or identification of nucleic acids involving differential detection
• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids
• G16B 30/10 - Sequence alignmentHomology search

Goods & Services

Recorded computer software for sharing of data and information in the field of animal health Education services, namely, providing training programs and courses in the field of animal health Providing temporary use of on-line non-downloadable software and applications for sharing of data and information in the field of animal health

Goods & Services

Downloadable computer software and downloadable mobile applications for assisting patients with symptoms of central nervous system diseases and disorders; downloadable computer software and downloadable mobile applications to assist patients with mental illness and disorders. Therapeutic services for patients with symptoms of diseases and disorders of the central nervous system; therapeutic services for patients to support mental health.

Goods & Services

Organization and conducting of workshops, seminars and training courses for medical care, prevention, and healthcare management in the field of mental health disorders, including online and via the internet. Medical services in the field of mental health disorders; providing medical support in the monitoring of patients with mental health disorders; health counselling, individual medical counseling services provided to patients in the field of mental health disorders.

Abstract

177 are as herein defined.

IPC Classes  ?

• C07D 309/10 - Oxygen atoms
• C07C 41/48 - Preparation of compounds having groups
• C07C 43/13 - Saturated ethers containing hydroxy or O-metal groups
• C07C 43/313 - Compounds having groups containing halogen
• C07C 69/734 - Ethers
• C07C 303/28 - Preparation of esters or amides of sulfuric acidsPreparation of sulfonic acids or of their esters, halides, anhydrides or amides of esters of sulfonic acids by reaction of hydroxy compounds with sulfonic acids or derivatives thereof
• C07D 498/14 - Ortho-condensed systems

Goods & Services

Vaccines for poultry.

Goods & Services

Pharmaceutical preparations.

Goods & Services

Pharmaceutical preparations.

Abstract

The present invention relates to a process for the manufacture of a HER2 inhibitor and compounds that are useful as intermediates in this process.

IPC Classes  ?

• C07D 487/04 - Ortho-condensed systems

Goods & Services

Organization and conducting of workshops, seminars and training courses for medical care, prevention and healthcare management in the field of stroke diseases, including online and via the Internet. Medical services in the field of stroke diseases.

Goods & Services

Pharmaceutical preparations.

Abstract

The present invention relates to new [1,3]diazino[5,4-d]pyrimidines and derivatives of Formula (I) The present invention relates to new [1,3]diazino[5,4-d]pyrimidines and derivatives of Formula (I) The present invention relates to new [1,3]diazino[5,4-d]pyrimidines and derivatives of Formula (I) wherein the groups R1, R2, R3 and R4 have the meanings given in the claims and specification, their use as inhibitors of HER2 and its mutants, pharmaceutical compositions which contain such compounds and their use as medicaments, especially as agents for treatment and/or prevention of oncological diseases.

IPC Classes  ?

• C07D 487/04 - Ortho-condensed systems
• A61K 47/26 - Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharidesDerivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
• A61K 47/32 - Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers
• A61K 47/36 - PolysaccharidesDerivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
• C07D 519/00 - Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups or

Goods & Services

Scientific research in the field of prevention and treatment of metabolic and cardiovascular diseases; providing medical and scientific research information in the field of metabolic and cardiovascular diseases.

Abstract

A viral inactivation device including at least one experimental continuous viral inactivation reactor having at least an inlet, an outlet, and a tubular flow path and a computer system that, based on the experimental continuous viral inactivation reactor can design, select, make, and/or manufacture a scaled actual reactor. The tubular flow path includes a set of alternating turns that form a serpentine or an interwoven pattern between the inlet and the outlet.

IPC Classes  ?

• C12M 1/36 - Apparatus for enzymology or microbiology including condition or time responsive control, e.g. automatically controlled fermentors
• C12M 1/00 - Apparatus for enzymology or microbiology
• C12M 1/34 - Measuring or testing with condition measuring or sensing means, e.g. colony counters

Abstract

The present invention generally relates to the field of recombinant gene expression in host cells. In particular, the invention relates to a recombinant human myeloid-derived growth factor (MYDGF) protein that exhibits a minimal degree of degradation upon expression in a host cell. The recombinant protein is therefore highly suitable for medical use, in particular for treating heart tissue damage and preventing cell death in myocardial tissue. The invention also provides a nucleic acid which encodes the recombinant protein and a host cell that expresses the recombinant protein. The invention also provides a method for producing the recombinant protein in a host cell.

IPC Classes  ?

• C07K 14/475 - Growth factorsGrowth regulators
• A61K 38/18 - Growth factorsGrowth regulators

Abstract

The present disclosure relates to the treatment of cancer by using an anti-SIRPα (Signal regulatory protein alpha) antibody or antigen-binding fragment thereof. In particular, the present disclosure relates to a method of using and uses of an anti-SIRPα antibody or antigen-binding fragment thereof to treat cancer including, in a treatment regimen that optionally includes the administration of an additional therapeutic agent.

IPC Classes  ?

• A61P 35/00 - Antineoplastic agents
• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants

Abstract

The present disclosure relates to the treatment of a SIRPα (signal regulatory protein alpha) pathway disease or disorder, such as a liver disease or disorder, by administering an anti-SIRPα antibody or antigen-binding fragment thereof to a subject in need thereof.

IPC Classes  ?

• A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants

Goods & Services

Downloadable computer software and downloadable mobile applications for assisting patients with symptoms of central nervous system diseases and disorders; downloadable computer software and downloadable mobile applications to assist patients with mental illness and disorders. Therapeutic services for patients with symptoms of diseases and disorders of the central nervous system; therapeutic services for patients to support mental health.

Abstract

This invention relates to compounds of Formula (I) useful as synthons for a general synthetic method for making chiral phosphorothioates, to their preparation and to their use in a robust large scale process for making P-chiral phosphorothioates. This invention relates to compounds of Formula (I) useful as synthons for a general synthetic method for making chiral phosphorothioates, to their preparation and to their use in a robust large scale process for making P-chiral phosphorothioates.

IPC Classes  ?

• C07F 9/58 - Pyridine rings
• C07H 1/02 - Phosphorylation
• C07H 19/10 - Pyrimidine radicals with the saccharide radical being esterified by phosphoric or polyphosphoric acids
• C07H 19/20 - Purine radicals with the saccharide radical being esterified by phosphoric or polyphosphoric acids
• C07H 21/04 - Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical

Goods & Services

Scientific research in the field of prevention and treatment of cardiovascular diseases; providing medical and scientific research information in the field of cardiovascular diseases.

Goods & Services

Downloadable computer software and downloadable mobile applications for assisting patients with symptoms of central nervous system diseases and disorders; downloadable computer software and downloadable mobile applications to assist patients with mental illness and disorders. Therapeutic services for patients with symptoms of diseases and disorders of the central nervous system; therapeutic services for patients to support mental health.

Abstract

A resin composite 10 according to the present invention includes: a coating powder 20 used in an electrostatic coating method or a fluidized immersion coating method; an inorganic alkali 30; and a thermoplastic resin 40. The coating powder 20 includes a thermal film-forming resin 26 and a crosslinking agent, and can be molded by one of the following molding methods: injection molding, blow molding, extrusion molding, and vacuum molding.

IPC Classes  ?

• C08L 101/00 - Compositions of unspecified macromolecular compounds
• C08J 3/205 - Compounding polymers with additives, e.g. colouring in the presence of a liquid phase
• C08J 5/00 - Manufacture of articles or shaped materials containing macromolecular substances
• C08K 3/22 - OxidesHydroxides of metals
• C08K 3/26 - CarbonatesBicarbonates
• C08L 67/00 - Compositions of polyesters obtained by reactions forming a carboxylic ester link in the main chainCompositions of derivatives of such polymers
• C09D 5/03 - Powdery paints
• C09D 7/61 - Additives non-macromolecular inorganic
• C09D 201/00 - Coating compositions based on unspecified macromolecular compounds

Goods & Services

Scientific research in the field of prevention and treatment of cardiovascular diseases; providing medical and scientific research information in the field of cardiovascular diseases.

Abstract

The present invention relates to a method for structure elucidation of the structure of an unknown chemical compound from a measured spectrum of a sample. The method includes at least one machine learning model, in particular a first machine learning model that generates structures of chemical compounds and/or a second machine learning model that generates predicted spectra from the structures.

IPC Classes  ?

• G16C 20/20 - Identification of molecular entities, parts thereof or of chemical compositions
• G06N 3/042 - Knowledge-based neural networksLogical representations of neural networks
• G06N 3/045 - Combinations of networks
• G06N 3/0464 - Convolutional networks [CNN, ConvNet]
• G06N 3/0475 - Generative networks
• G06N 3/094 - Adversarial learning
• G16C 20/70 - Machine learning, data mining or chemometrics

Goods & Services

Scientific research in the field of prevention and treatment of metabolic and cardiovascular diseases; providing medical and scientific research information in the field of metabolic and cardiovascular diseases..

Abstract

The present disclosure provides cis-5-(hydroxymethyl)morpholine-2-carboxamides that are agonists of somatostatin receptor 4 (SSTR4), and are therefore useful for the treatment of diseases or medical conditions associated with SSTR4. Also provided are pharmaceutical compositions containing the same, and processes for preparing said compounds. The present disclosure provides cis-5-(hydroxymethyl)morpholine-2-carboxamides that are agonists of somatostatin receptor 4 (SSTR4), and are therefore useful for the treatment of diseases or medical conditions associated with SSTR4. Also provided are pharmaceutical compositions containing the same, and processes for preparing said compounds.

IPC Classes  ?

• C07D 265/30 - 1,4-OxazinesHydrogenated 1,4-oxazines not condensed with other rings
• A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• C07D 413/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Abstract

The present invention relates to processes for preparing glucopyranosyl-substituted benzyl-benzene derivatives of general formula III, The present invention relates to processes for preparing glucopyranosyl-substituted benzyl-benzene derivatives of general formula III, The present invention relates to processes for preparing glucopyranosyl-substituted benzyl-benzene derivatives of general formula III, wherein R1, R2 and R′ are defined according to claim 1; and the use of such processes in the synthesis of SGLT2 inhibitors.

IPC Classes  ?

• C07H 1/00 - Processes for the preparation of sugar derivatives
• C07H 7/00 - Compounds containing non-saccharide radicals linked to saccharide radicals by a carbon-to-carbon bond

Abstract

The present invention relates to anti-IL-23p19 binding compounds, in particular new humanized anti-IL-23p19 antibodies and therapeutic and diagnostic methods and compositions for using the same.

IPC Classes  ?

• C07K 16/24 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides

Abstract

Methods of protein production in a linked culture and production bioreactor system are provided. Such methods include a culture bioreactor (N-1 bioreactor) linked to production bioreactor (N bioreactor). More specifically, the methods include (a) culturing cells with a gene that encodes the protein of interest in a continuous perfusion culture bioreactor (N-1 bioreactor); inoculating a continuously stirred tank reactor (CSTR) production bioreactor (N bioreactor) with cells obtained from step (a); and culturing the cells in the CSTR production bioreactor under conditions that allow production of the protein of interest.

IPC Classes  ?

• C12M 1/00 - Apparatus for enzymology or microbiology
• C07K 16/00 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies
• C12M 1/06 - Apparatus for enzymology or microbiology with gas introduction means with agitator, e.g. impeller
• C12N 5/00 - Undifferentiated human, animal or plant cells, e.g. cell linesTissuesCultivation or maintenance thereofCulture media therefor
• C12N 5/071 - Vertebrate cells or tissues, e.g. human cells or tissues
• C12P 21/02 - Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione

Abstract

The present disclosure provides certain tetrazole derivatives that are inhibitors of transient receptor potential ankyrin 1 (TRPA1), and are therefore useful for the treatment of diseases treatable by inhibition of TRPA1. Also provided are pharmaceutical compositions containing the same, and processes for preparing said compounds.

IPC Classes  ?

• C07D 403/06 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
• C07D 403/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
• C07D 405/14 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
• C07D 409/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
• C07D 413/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Abstract

Methods of treating or preventing alcoholic liver disease are disclosed, the methods comprising administering to a subject a therapeutically or prophylactically effective amount of an agent capable of inhibiting interleukin 11 (IL-11)-mediated signalling.

IPC Classes  ?

• C07K 16/24 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
• A61K 38/20 - Interleukins
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides

Goods & Services

Medical and scientific research in the fields of respiratory diseases, inflammatory diseases and autoimmune diseases; providing medical and scientific research information in the field of respiratory diseases, inflammatory diseases and autoimmune diseases.

Goods & Services

Downloadable computer software and downloadable mobile applications for assisting patients with symptoms of central nervous system diseases and disorders; downloadable computer software and downloadable mobile applications to assist patients with mental illness and disorders. Therapeutic services for patients with symptoms of diseases and disorders of the central nervous system; therapeutic services for patients to support mental health.

Goods & Services

Downloadable computer software and downloadable mobile applications for assisting patients with symptoms of central nervous system diseases and disorders; downloadable computer software and downloadable mobile applications to assist patients with mental illness and disorders. Therapeutic services for patients with symptoms of diseases and disorders of the central nervous system; therapeutic services for patients to support mental health.

Abstract

The present invention relates to the finding that certain DPP-4 inhibitors are particularly suitable for treating and/or preventing metabolic diseases, particularly diabetes, in patients with insufficient glycemic control despite a therapy with an oral and/or a non-oral antidiabetic drug.

IPC Classes  ?

• A61K 31/522 - Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 31/155 - Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (HN=C(OH)NH2), isothiourea (HN=C(SH)—NH2)
• A61K 31/4439 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
• A61K 31/64 - Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
• A61K 38/28 - Insulins
• A61P 3/10 - Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Abstract

The present invention relates to a HER2 inhibitor useful in the prevention and/or treatment of cancer, in particular, to methods of treatment or uses comprising avoiding, contraindicating, reducing or discontinuing concomitant use or co-administration of a CYP3A and/or P-gp modulator. The present invention also relates to a HER2 inhibitor useful in the prevention and/or treatment of cancer, in particular, to methods of treatment or uses comprising concomitant use, co-administration or combination of a CYP3A and/or P-gp modulator.

IPC Classes  ?

• A61K 31/4995 - Pyrazines or piperazines forming part of bridged ring systems
• A61K 31/03 - Halogenated hydrocarbons carbocyclic aromatic
• A61K 31/4468 - Non-condensed piperidines, e.g. piperocaine having a nitrogen atom directly attached in position 4, e.g. clebopride, fentanyl
• A61K 31/573 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
• A61P 35/00 - Antineoplastic agents

Goods & Services

Downloadable computer software and downloadable mobile applications for assisting patients with symptoms of central nervous system diseases and disorders by providing lessons and techniques to treat and manage negative symptoms; downloadable computer software and downloadable mobile applications to assist patients with mental illness and disorders by providing lessons and techniques to treat and manage negative symptoms. Therapeutic healthcare services for patients with symptoms of diseases and disorders of the central nervous system; therapeutic healthcare services for patients to support mental health.

Goods & Services

Scientific research in the field of prevention and treatment of metabolic and cardiovascular diseases; providing medical and scientific research information in the field of metabolic and cardiovascular diseases..

Goods & Services

Scientific research in the field of prevention and treatment of cardiovascular diseases; providing medical and scientific research information in the field of cardiovascular diseases..

Abstract

The present invention provides recombinant herpes virus of turkeys (HVT) viral vectors comprising a heterologous polynucleotide encoding an avian influenza antigen. The recombinant viral vectors are suitable for use in immunogenic compositions and vaccines, and can provide protection against avian influenza and other pathogens when administered to an avian.

IPC Classes  ?

• A61K 39/12 - Viral antigens
• A61P 31/14 - Antivirals for RNA viruses
• A61P 31/16 - Antivirals for RNA viruses for influenza or rhinoviruses
• A61P 31/20 - Antivirals for DNA viruses
• C12N 7/00 - Viruses, e.g. bacteriophagesCompositions thereofPreparation or purification thereof

Abstract

The present invention relates to the protein myeloid-derived growth factor (MYDGF) or nucleic acids encoding said protein for use in treating or preventing a liver disorder. The present invention also relates to vectors comprising the nucleic acid, host cells expressing the nucleic acid, and methods for use in treating a liver disorder.

IPC Classes  ?

• A61K 38/18 - Growth factorsGrowth regulators
• A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
• A61K 31/70 - CarbohydratesSugarsDerivatives thereof
• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy

Abstract

The present invention relates to methods for preventing or treating acute or chronic heart failure and for reducing the risk of cardiovascular death, hospitalization for heart failure and other conditions in patients with preserved or reduced ejection fraction by administering empagliflozin to the patient.

IPC Classes  ?

• A61K 31/351 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
• A61K 9/20 - Pills, lozenges or tablets
• A61K 31/7048 - Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Abstract

The present invention provides recombinant Newcastle disease virus (NDV) viral vectors comprising a heterologous polynucleotide encoding an avian influenza antigen. The recombinant viral vectors are suitable for use in immunogenic compositions and vaccines, and can provide protection against avian influenza and other pathogens when administered to an avian.

IPC Classes  ?

• A61K 39/12 - Viral antigens
• A61P 31/14 - Antivirals for RNA viruses
• A61P 31/16 - Antivirals for RNA viruses for influenza or rhinoviruses

Abstract

The present invention provides recombinant canine distemper virus (CDV) viral vectors comprising a heterologous polynucleotide encoding an avian influenza antigen. The recombinant viral vectors are suitable for use in immunogenic compositions and vaccines, and can provide protection against avian influenza and other pathogens when administered to an animal.

IPC Classes  ?

• A61K 39/12 - Viral antigens
• A61P 31/14 - Antivirals for RNA viruses
• A61P 31/16 - Antivirals for RNA viruses for influenza or rhinoviruses
• C07K 14/005 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from viruses

Goods & Services

Organization and conducting of workshops, seminars and training courses for medical care, prevention and healthcare management in the field of stroke diseases, including online and via the Internet. Medical services in the field of stroke diseases.

Goods & Services

(1) Organization and conducting of workshops, seminars and training courses for medical care, prevention and healthcare management in the field of stroke diseases, including online and via the Internet. (2) Medical services in the field of stroke diseases.

Goods & Services

Downloadable computer software and downloadable mobile applications for assisting patients with symptoms of central nervous system diseases and disorders; downloadable computer software and downloadable mobile applications to assist patients with mental illness and disorders. Therapeutic services for patients with symptoms of diseases and disorders of the central nervous system; therapeutic services for patients to support mental health.

Goods & Services

Downloadable computer software and downloadable mobile applications for assisting patients with symptoms of central nervous system diseases and disorders; downloadable computer software and downloadable mobile applications to assist patients with mental illness and disorders. Therapeutic services for patients with symptoms of diseases and disorders of the central nervous system; therapeutic services for patients to support mental health.

Abstract

The invention relates to a method for purifying and enriching a target product selected from immunoglobulins or other proteins; or plasmid DNA, genomic DNA, RNA or other nucleic acids or viruses, wherein the measured electrical conductivity values and/or the measured turbidity values of the phases are used for adjusting the position of the phases in a separating device (10, 100) and for separating the phases. The invention also relates to a device for carrying out the method and to the use thereof.

IPC Classes  ?

• B01D 17/04 - Breaking emulsions
• B01D 11/04 - Solvent extraction of solutions which are liquid
• B01D 17/12 - Auxiliary equipment particularly adapted for use with liquid-separating apparatus, e.g. control circuits
• C12N 15/10 - Processes for the isolation, preparation or purification of DNA or RNA
• G01N 27/02 - Investigating or analysing materials by the use of electric, electrochemical, or magnetic means by investigating impedance

Abstract

The present invention relates i.a. to an IBV (infectious bronchitis virus) encoding for a heterologous DMV S (spike) protein or fragment thereof. Further, the present invention relates to an immunogenic composition comprising said IBV encoding for a heterologous DMV S (spike) protein or fragment thereof. Furthermore, the present invention relates to methods for immunizing a subject comprising administering to such subject the immunogenic composition of the present invention. Moreover, the present invention relates to methods of treating or preventing clinical signs caused by IBV in a subject of need, the method comprising administering to the subject a therapeutically effective amount of an immunogenic composition according to the present invention.

IPC Classes  ?

• A61K 39/215 - Coronaviridae, e.g. avian infectious bronchitis virus
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61P 31/14 - Antivirals for RNA viruses
• C07K 14/005 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from viruses
• C12N 7/00 - Viruses, e.g. bacteriophagesCompositions thereofPreparation or purification thereof

Abstract

The present invention relates to pharmaceutical compositions of DPP IV inhibitors with an amino group, their preparation and their use to treat diabetes mellitus.

IPC Classes  ?

• A61K 31/522 - Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 9/20 - Pills, lozenges or tablets
• A61K 9/28 - DrageesCoated pills or tablets
• A61K 31/517 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine

Abstract

The specification describes the use of selected DPP IV inhibitors for the treatment of physiological functional disorders and for reducing the risk of the occurrence of such functional disorders in at-risk patient groups. In addition, the use of the above-mentioned DPP IV inhibitors in conjunction with other active substances is described, by means of which improved treatment outcomes can be achieved. These applications may be used to prepare corresponding medicaments.

IPC Classes  ?

• A61K 31/522 - Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
• A61K 31/155 - Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (HN=C(OH)NH2), isothiourea (HN=C(SH)—NH2)
• A61K 31/197 - Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
• A61K 31/4184 - 1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
• A61K 31/4985 - Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
• A61K 31/5025 - PyridazinesHydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
• A61K 31/52 - Purines, e.g. adenine
• A61K 31/7048 - Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Goods & Services

Scientific research in the field of prevention and treatment of cardiovascular diseases; providing medical and scientific research information in the field of cardiovascular diseases.

Abstract

The present disclosure provides certain piperidinylpyridinylcarbonitrile derivatives, and pharmaceutically acceptable salts thereof, that are inhibitors of Glutaminyl-peptide cyclotransferase (QPCT) and glutaminyl-peptide cyclotransferase-like protein (QPCTL), and are therefore useful for the treatment of diseases treatable by inhibition of QPCT/L. Also provided are pharmaceutical compositions containing the same, and processes for preparing said compounds.

IPC Classes  ?

• C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
• A61K 31/4545 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
• A61K 31/501 - PyridazinesHydrogenated pyridazines not condensed and containing further heterocyclic rings
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• C07D 471/04 - Ortho-condensed systems

Abstract

A method, being executed by a computer or signal processor or system or apparatus, for processing a first video data set comprising first video data of a first video depicting a plurality of moving objects. The method comprises generating one or more further video data sets from the first video data set, such that each further video data set of the one or more further video data sets comprises further video data of a further video, such that exactly one moving object of the plurality of moving objects is associated with said further video data set.

IPC Classes  ?

• G06T 7/20 - Analysis of motion

Abstract

Disclosed are methods for treating focal segmental glomerulosclerosis (FSGS), comprising administering to a patient in need thereof a pharmaceutically effective amount of a compound of formula (I), wherein R1 to R7, A, L and Y are as defined herein. Also disclosed are pharmaceutical compositions comprising the compound of formula (I) and their use for treating FSGS.

IPC Classes  ?

• A61K 31/501 - PyridazinesHydrogenated pyridazines not condensed and containing further heterocyclic rings
• A61P 13/12 - Drugs for disorders of the urinary system of the kidneys

Abstract

The present disclosure provides certain piperidinylpyridinylcarbonitrile derivatives, and pharmaceutically acceptable salts thereof, that are inhibitors of Glutaminyl-peptide cyclotransferase (QPCT) and glutaminyl-peptide cyclotransferase-like protein (QPCTL), and are therefore useful for the treatment of diseases treatable by inhibition of QPCT/L. Also provided are pharmaceutical compositions containing the same, and processes for preparing said compounds.

IPC Classes  ?

• C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
• A61K 31/4545 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
• A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• C07D 471/04 - Ortho-condensed systems
• C07D 487/04 - Ortho-condensed systems

Abstract

The present disclosure provides certain piperidinylpyridinylcarbonitrile derivatives, and pharmaceutically acceptable salts thereof, that are inhibitors of Glutaminyl-peptide cyclotransferase (QPCT) and glutaminyl-peptide cyclotransferase-like protein (QPCTL), and are therefore useful for the treatment of diseases treatable by inhibition of QPCT/L. Also provided are pharmaceutical compositions containing the same, and processes for preparing said compounds.

IPC Classes  ?

• C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
• C07D 471/04 - Ortho-condensed systems
• A61K 31/444 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. amrinone
• A61P 35/00 - Antineoplastic agents

Abstract

The present invention relates to methods for using soluble guanylate cyclase (sGC) activators for preventing, slowing the progression of, delaying or treating clinically significant portal hypertension (CSPH) and decompensated cirrhosis due to non-cholestatic liver disease.

IPC Classes  ?

• A61K 31/4155 - 1,2-Diazoles not condensed and containing further heterocyclic rings
• A61K 31/4439 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
• A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
• A61P 9/12 - Antihypertensives

Abstract

The present disclosure provides certain piperidinylpyridinylcarbonitrile derivatives, and pharmaceutically acceptable salts thereof, that are inhibitors of Glutaminyl-peptide cyclotransferase (QPCT) and glutaminyl-peptide cyclotransferase-like protein (QPCTL), and are therefore useful for the treatment of diseases treatable by inhibition of QPCT/L. Also provided are pharmaceutical compositions containing the same, and processes for preparing said compounds.

IPC Classes  ?

• C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
• A61K 31/4545 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
• A61K 31/5025 - PyridazinesHydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
• A61K 31/506 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
• A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• C07D 413/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
• C07D 471/04 - Ortho-condensed systems
• C07D 487/04 - Ortho-condensed systems
• C07D 491/048 - Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
• C07D 498/04 - Ortho-condensed systems

Abstract

Disclosed are methods for treating focal segmental glomerulosclerosis (FSGS), comprising administering to a patient in need thereof a pharmaceutically effective amount of a compound of formula (I), Disclosed are methods for treating focal segmental glomerulosclerosis (FSGS), comprising administering to a patient in need thereof a pharmaceutically effective amount of a compound of formula (I), Disclosed are methods for treating focal segmental glomerulosclerosis (FSGS), comprising administering to a patient in need thereof a pharmaceutically effective amount of a compound of formula (I), wherein R1 to R7, A, L and Y are as defined herein. Also disclosed are pharmaceutical compositions comprising the compound of formula (I) and their use for treating FSGS.

IPC Classes  ?

• A61K 31/4545 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
• A61K 31/496 - Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
• A61K 31/499 - Spiro-condensed pyrazines or piperazines
• A61K 31/4995 - Pyrazines or piperazines forming part of bridged ring systems
• A61K 31/501 - PyridazinesHydrogenated pyridazines not condensed and containing further heterocyclic rings
• A61K 31/5386 - 1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems

Abstract

The present invention relates to the field of oncolytic viruses and in particular to a recombinant rhabdovirus, such as vesicular stomatitis virus encoding in its genome for a CD80 extracellular domain Fc-fusion protein. The invention is further directed to the use of the recombinant virus in the treatment of cancer, and also to methods for producing such viruses.

IPC Classes  ?

• A61K 35/766 - Rhabdovirus, e.g. vesicular stomatitis virus
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• C07K 14/705 - ReceptorsCell surface antigensCell surface determinants

Abstract

Methods of protein production in continuous perfusion mammalian cell culture bioreactors are provided. Methods for continuous perfusion culture by allowing cells to self-regulate the rate of addition of perfusion medium to the bioreactor via a pH change are presented. Compositions comprising the perfusion medium as well as the process advantages of using hi-end pH control of perfusion or HIPCOP are also presented.

IPC Classes  ?

• C12M 1/00 - Apparatus for enzymology or microbiology
• C12M 1/34 - Measuring or testing with condition measuring or sensing means, e.g. colony counters
• C12N 5/00 - Undifferentiated human, animal or plant cells, e.g. cell linesTissuesCultivation or maintenance thereofCulture media therefor

Abstract

This invention relates to binding molecules that bind specifically Vascular Endothelial Growth Factor (VEGF) and Tropomyosin receptor kinase B (TrkB) and their use in medicine, pharmaceutical compositions comprising the same, and methods of using the same as agents for treatment and/or prevention of diseases of the eye.

IPC Classes  ?

• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61P 27/02 - Ophthalmic agents
• C07K 16/22 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors

Abstract

The present invention relates to treatment of chronic kidney disease by administering to patients in need thereof a compound of formula (I): The present invention relates to treatment of chronic kidney disease by administering to patients in need thereof a compound of formula (I): The present invention relates to treatment of chronic kidney disease by administering to patients in need thereof a compound of formula (I): and pharmaceutically acceptable salts thereof, wherein Cy, R1 and R2 are as defined herein. The invention further relates to the use of the compounds of formula (I) in combination with sodium-glucose cotransporter-2 (SGLT2) inhibitors.

IPC Classes  ?

• A61K 31/4188 - 1,3-Diazoles condensed with heterocyclic ring systems, e.g. biotin, sorbinil
• A61K 31/4709 - Non-condensed quinolines containing further heterocyclic rings
• A61P 13/12 - Drugs for disorders of the urinary system of the kidneys